COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS

A. V. Rudakova
2015 PHARMACOECONOMICS Modern pharmacoeconomics and pharmacoepidemiology  
results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.
doaj:a4e3fc198e2b4a03a3ec0fe682b3724b fatcat:jdn3567r7nepnkmkn7poxsbkp4